| Literature DB >> 27891251 |
Nikolaos A Chatzizacharias1, Khaled Dajani1, Jun Kit Koong2, Asif Jah1.
Abstract
Introduction. Single incision laparoscopic surgery (SILS) has gained increasing support over the last few years. The aim of this narrative review is to analyse the published evidence on the use and potential benefits of SILS in hepatic and pancreatic resectional surgery for benign and malignant pathology. Methods. Pubmed and Embase databases were searched using the search terms "single incision laparoscopic", "single port laparoscopic", "liver surgery", and "pancreas surgery". Results. Twenty relevant manuscripts for liver and 9 for pancreatic SILS resections were identified. With regard to liver surgery, despite the lack of comparative studies with other minimal invasive techniques, outcomes have been acceptable when certain limitations are taken into account. For pancreatic resections, when compared to the conventional laparoscopic approach, SILS produced comparable results with regard to intra- and postoperative parameters, including length of hospitalisation and complications. Similarly, the results were comparable to robotic pancreatectomies, with the exception of the longer operative time reported with the robotic approach. Discussion. Despite the limitations, the published evidence supports that SILS is safe and feasible for liver and pancreatic resections when performed by experienced teams in the tertiary setting. However, no substantial benefit has been identified yet, especially compared to other minimal invasive techniques.Entities:
Year: 2016 PMID: 27891251 PMCID: PMC5116530 DOI: 10.1155/2016/1454026
Source DB: PubMed Journal: Minim Invasive Surg ISSN: 2090-1445
Figure 1Published evidence on the use of SILS in liver resectional surgery.
| Procedure (number) | Indication (number) | Location of lesion (number) | Size of lesion (mm) (median and range) or (mean ± SD) | Conversion rate (%) | Operative time (min) (median and range) or (mean ± SD) | Blood loss (mL) (median and range) or (mean ± SD) | LOS (days) (median and range) or (mean ± SD) | Complications (number) | |
|---|---|---|---|---|---|---|---|---|---|
| Claude et al., 2014 [ | NALR (7) | FNA (1) | Segment III (2) | 20 (20–47) | 0 | 110 (60–150) | 50 (25–150) | 5 (1–13) | 0 |
|
| |||||||||
| Tzanis et al., 2014 [ | LLR (1) | Adenoma (1) | Segment II/III (1) | 38 (12–90) | 0 | 110 (100–120) | <50 (<50–150) | 3 (1–3) | 1 (allergic reaction) |
|
| |||||||||
| Wu et al., 2014 [ | Proximal left (1) | HM (8) | Segment II (3) | 49 (20–105) | 0 | 117.9 (55–185) | 256.5 (30–830) | 7 (3–10) | Pleural effusion (2) |
|
| |||||||||
| Shetty et al., 2012 [ | NALR (6) | HCC (23) | Segment I/VI (2) | 36 (10–90) | 26 | 205 (95–545) | 500 (100–2500) | 8 (5–16) | Bile leak (1) |
|
| |||||||||
| Røsok and Edwin, 2011 [ | NALR(1) | CRCLM (1) | Segment V (1) | 15 | 0 | — | 120 | 5 | Pulmonary oedema (1) |
|
| |||||||||
| Toyama et al., 2013 [ | NALR (1) | HCC/CCA (1) | Segment VI (1) | 30 | 0 | 180 | Minimal | — | None |
|
| |||||||||
| Kobayashi et al., 2010 [ | NALR (1) | HCC (1) | Segment III (1) | 20 | 0 | 70 | Minimal | 1 | None |
|
| |||||||||
| Belli et al., 2011 [ | NALR (1) | HCC (1) | Segment III (1) | — | 0 | 130 | Minimal | 2 | None |
|
| |||||||||
| Pan et al., 2012 [ | LLR (3) | HCC (4) | Segment II/III (4) | 47 (35–110) | 0 | 89 (67–123) | 58 (50–100) | 3 (2–6) | None |
|
| |||||||||
| Camps Lasa et al., 2014 [ | LH (1) | CRCLM (4) | Segment II (1) | 24 (7–62) | 0 | 135 (120–210) | — | 3 (3-4) | None |
|
| |||||||||
| Kim et al., 2014 [ | LLR (1) | HCC (3) | Segment II (2) | 17 (10–36) | 0 | 227 (142–228) | 200 (200–250) | 7 (3–8) | Pleural effusion (1) |
|
| |||||||||
| Hu et al., 2011 [ | LLR (1) | HM (2) | Segment II/III (1) | 48 (15–80) | 0 | 120 | 100 | 3 | None |
|
| |||||||||
| Gaujoux et al., 2011 [ | LH (3) | HCC (1) | Segment III (1) | 14 (13–20) | 0 | 115 (55–140) | 38 (20–50) | 2 | None |
|
| |||||||||
| Kim et al., 2013 [ | LLR (1) | CRCLM (1) | Segments II/III (1) | 80 | 0 | 315 (synchronous high anterior resection) | — | 11 | Atelectasis (1) |
|
| |||||||||
| Machado et al., 2014 [ | LLR (8) | Adenoma (6) | — | — | 0 | 68 (45–100) | <100 | 1 (1-2) | None |
|
| |||||||||
| Dapri et al., 2012 [ | LLR (1) | Hydatid (2) | Segment II/III (1) | — | 0 | 158 (114–185) | 350 (200–500) | 5 (4-5) | None |
|
| |||||||||
| Zhao et al., 2011 [ | LLR (4) | HCC (2) | Segment II/III (3) | 44 ± 26 (11–96) | 17 | 80.4 ± 38.3 (35–160) | 45 (20–800) | 4 ± 1 (2–8) | Massive haemorrhage (1) |
|
| |||||||||
| Cai et al., 2010 [ | NALR (1) | HM (1) | Segment II/III (1) | 38 | 0 | 75 | 80 | 2 | None |
|
| |||||||||
| Aldrighetti et al., 2011 [ | LLR (1) | CRCLM (1) | Segment II/III (1) | 35 | 0 | 145 | 50 | 4 | None |
|
| |||||||||
| Aikawa et al., 2012 [ | NALR (8) | HCC (5) | Segment II (1) | 15 (9–30) | 0 | 148 (141–235) | 2 (0–10) | 6 (3–11) | None |
NALR: nonanatomical liver resection, LLR: left lateral resection, LH: left hepatectomy, RH: right hepatectomy, SLR: segmental liver resection, CRCLM: colorectal cancer liver metastasis, HCC: hepatocellular carcinoma, FNH: focal nodular hyperplasia, HM: haemangioma, CCA: cholangiocarcinoma.
Published evidence on the use of SILS in pancreatic resectional surgery.
| Procedure (number) | Indication (number) | Size of lesion (mm) (median and range) or (mean ± SD) | Conversion rate (%) | Operative time (min) (median and range) or (mean ± SD) | Blood loss (mL) (median and range) or (mean ± SD) | LOS (days) (median and range) or (mean ± SD) | Complications (number) | |
|---|---|---|---|---|---|---|---|---|
| Barbaros et al., 2010 [ | DP+S (1) | RCC metastases (2) | 23 (15–30) | 0 | 330 | 100 | 7 | POPF grade A (1) |
|
| ||||||||
| Chang et al., 2012 [ | DP (1) | SCN (1) | 35 | 0 | 233 | <100 | 3 | None |
|
| ||||||||
| Haugvik et al., 2013 [ | DP (5) | 5 NET (5) | 21 (10–45) | 0 | 145 (98–223) | 225 (30–400) | 6 (3–15) | Port site infection (1) |
|
| ||||||||
| Machado et al., 2015 [ | DP (18) | NET (11) | 31 (9–70) | 0 | 176 (110–340) | <50 (<50–250) | 2 (1–5) | POPF grade A (4) |
|
| ||||||||
| Misawa et al., 2012 [ | DP (1) | Cystadenoma (1) | 50 (35–65) | 0 | 240 | 0 | 7 | None |
| DP+S (1) | MCN (1) | 0 | 225 | 100 | 5 | None | ||
|
| ||||||||
| Ryan et al., 2015 [ | DP+S (16) | PDA (3) | 38 ± 30 (8–117) | 19 | 190 (197 ± 40.7) | 150 (246 ± 263.9) | 4 (6 ± 3.8) | AF (1) |
|
| ||||||||
| Srikanth et al., 2013 [ | DP+S (1) | NET (1) | 35 | 0 | — | — | 5 | Collection (1) |
|
| ||||||||
| Yao et al., 2014 [ | DP+S (7) | MCN (6) | 43 ± 22 (12–110) | 7 | 166 ± 55 | 157 ± 162 | 7 ± 1 (5–10) | POPF grade A/B (1) |
|
| ||||||||
| Zhang et al., 2015 [ | Local excision (2) | Pancreatoblastoma (1) | — | 0 | 153 (120–200) | Minimal | 6-7 | None |
DP: distal pancreatectomy, DP+S: distal pancreatectomy and splenectomy, NET: neuroendocrine tumour, IPMN: intraductal papillary mucinous neoplasm, SCN: serous cystic neoplasm, MCN, mucinous cystic neoplasm, PDA: pancreatic ductal adenocarcinoma, HM: haemangioma, AF: atrial fibrillation, POPF: postoperative pancreatic fistula.